• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
【24h】

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer

机译：剂量密集型表柔比星和环磷酰胺，随后每周紫杉醇治疗淋巴结阳性乳腺癌。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined.Objectives. The feasibility of dose-dense epirubicin in combination with cyclophosphamide (EC) followed by weekly paclitaxel as adjuvant chemotherapy in node-positive breast cancer patients was investigated.Methods. All patients were treated with epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) every two weeks for four cycles with daily Pegfilgrastim (G-CSF) that was administered 3–10 days after each cycle of epirubicin and cyclophosphamide infusion which followed by (80 mg/m2) paclitaxel for twelve consecutive weeks.Results. Sixty consecutive patients were analyzed, of whom 57 patients (95%) completed the regimen and no case of toxicity-related death was observed. Grade 3/4 hematologic toxicity was uncommon and the most common grade 3/4 nonhematological adverse event was neuropathy disorders.Conclusions. Dose-dense epirubicin and cyclophosphamide followed by weekly paclitaxel with G-CSF support is a well-tolerated and feasible regimen in node-positive breast cancer patients without serious complications.
机译：背景。在以蒽环类为基础的辅助化疗中添加紫杉烷类药物对淋巴结阳性的乳腺癌患者显示出明显的改善，但最佳给药方案尚未确定。研究了剂量密集的表柔比星联合环磷酰胺（EC）联合每周紫杉醇作为淋巴结阳性乳腺癌患者辅助化疗的可行性。所有患者均每两周接受表柔比星（100μmg/ m2）和环磷酰胺（600μmg/ m2）的治疗，共四个周期，每天一次服用Pegfilgrastim（G-CSF），在每个周期的表柔比星和环磷酰胺输注后3-10天给药。随后连续十二周服用（80μmg/ m2）紫杉醇。分析了60位连续患者，其中57位患者（95％）完成了该方案，未观察到毒性相关死亡的病例。 3/4级血液学毒性很少见，最常见的3/4级非血液学不良事件是神经病变。在无严重并发症的淋巴结阳性乳腺癌患者中，剂量密集的表柔比星和环磷酰胺再加每周紫杉醇联合G-CSF支持是一种耐受良好且可行的方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号